In recent years, following the publication of results from several RCTs, first on cardiovascular and more recently on renal outcomes, SGLT2is have become the standard of care to prevent diabetic kidney disease and slow its progression. This narrative review focuses on biological mechanisms, both renal and extrarenal, underlying kidney protection with SGLT2is. Furthermore, data from cardiovascular as well as renal outcome trials, mostly conducted in diabetic patients, are presented and discussed to provide an overview of current uses as well as the future therapeutic potential of these drugs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122991 | PMC |
| http://dx.doi.org/10.3390/ijms22094441 | DOI Listing |
Publication Analysis
Top Keywords
biological mechanisms
8
sglt2is renal
4
renal protection
4
protection biological
4
mechanisms real-world
4
real-world clinical
4
clinical benefits
4
benefits years
4
years publication
4
publication rcts
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!